Erudio Healtherudio.com
Drug
PD-L1 t-haNK trials: what clinicians said in public
An HCP commentary report on 1 clinical trial studying PD-L1 t-haNK: QUILT-3.055. It covers what clinicians said in public about one trial, on podcasts, videos and posts, every statement linked to its source. Below them, 3 more trials with public commentary and no report yet.
| Trial | Indication | Phase | Statements | Sources | Size | Checked | Preview |
|---|---|---|---|---|---|---|---|
| QUILT-3.055 NCT03228667 · ImmunityBio, Inc. | cancer previously treated with immune checkpoint inhibitors | Phase 2 | 91 | 13 | Focused | Nov 20, 2026 | Preview |
| No report yetTrials with public commentary we haven't built a report for. Size is an estimate of the verified statements the commentary we've indexed so far will yield; final coverage is set when we build the report, within 24 hours of your confirmed order. You never pay more than quoted: a report delivered at a smaller size costs that size's price. Some can also be requested as a free preview. | |||||||
| QUILT-88 NCT04390399 · ImmunityBio, Inc. FocusedView → | Not given | Phase 2 | Focused | View | |||
| QUILT-3.078 NCT06061809 · ImmunityBio, Inc. FocusedView → | recurrent or progressive glioblastoma | Phase 2 | Focused | View | |||
| QUILT-505 NCT06239220 · Dana-Farber Cancer Institute FocusedView → | immunotherapy-treated recurrent metastatic HNSCC | Phase 2 | Focused | View | |||